Life Technologies Launches Oncomine® Bioinformatics Solutions for Cancer Researchers

   Life Technologies Launches Oncomine® Bioinformatics Solutions for Cancer
                                 Researchers

Oncomine® Gene Browser: Cost-effective option for academic, biotech and
smaller pharma researchers to search premier cancer genomics database for
expression, copy number and mutation data

Ion Reporter™ Oncomine® Workflow: End-to-end bioinformatics solution to
identify driver mutations for cancer research

PR Newswire

CARLSBAD, Calif., April 4, 2013

CARLSBAD, Calif., April 4, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) announced today the introduction of two bioinformatics
offerings - Oncomine(R) Gene Browser and Ion Reporter(TM) Oncomine(R) Workflow
- that will allow cancer researchers new avenues of access to one of the
largest genomics databases available, compiled by the former Compendia
Bioscience. Both products will be featured in Life Technologies' booth (#2222)
at the 2013 annual meeting of the American Association for Cancer Research
(AACR 2013), April 6 – 10 in Washington, D.C.

Oncomine® Gene Browser

Oncomine® Gene Browser enables cancer researchers to characterize their genes
of interest across multiple parameters, including gene expression, DNA copy
number and mutation data, from thousands of cancer patients' genetic data
(exomes and transcriptomes). The Oncomine® Gene Browser consists of a simple,
dynamic web portal and provides a comprehensive gene summary at a moderate
price point. It is ideal for researchers working with small numbers of genes
and enables the survey of individual genes across thousands of de-identified
clinical cases and dozens of different cancer types and subtypes.

The new product introduction exemplifies Life Technologies' commitment to
offering high-value products in the bioinformatics space across a range of
price options and demonstrates the company's ability to serve all customers in
the cancer research space, including basic, translational and clinical
scientists, as well as those working in the biotech and pharma industry.

"Oncomine® Gene Browser is a new product for the academic and smaller pharma
scientist that will enable them to be competitive in research and drug
development," said Dan Rhodes, head of medical bioinformatics for Life
Technologies. "These investigators will now have access to data that have been
collected and curated over the course of a decade, drawing from hundreds of
clinical studies and representing millions of dollars worth of experiments,
which will allow them to design more focused experiments and make faster
progress."

"Oncomine^® Gene Browser constitutes a unique solution for scientists working
in the drug discovery and companion diagnostics space," said Ronnie Andrews,
president of Medical Sciences at Life Technologies. "When combined with Life's
broad portfolio of instrument systems for cancer research, including our Ion
Torrent semiconductor based sequencing system and AmpliSeq Cancer Panels,
researchers now have an extremely robust system which will provide markedly
enhanced selection criteria to more rapidly advance their research."

Ion Reporter™ Oncomine® Workflow

The Ion Reporter™ Oncomine® Workflow streamlines cancer research by combining
its proven Oncomine^® platform with Ion Reporter^™ Software.It provides
access to curated next generation sequencing data from 4,000 matched tumor and
normal pairs and is designed to assist with interpreting variants from data
obtained on the Ion Torrent™ semi-conductor sequencing platforms from Life
Technologies.

Using the Ion Reporter^™ Oncomine^® workflow with Ion AmpliSeq^™ cancer
panels, such as the Cancer Hotspot Panel and the Comprehensive Cancer Panel,
enables researchers to move from sample to sequence to driver mutations in a
day, rather than weeks or months. The Ion Reporter^™ Oncomine^® Workflow will
be available at no charge for an introductory period, making this premier
cancer bioinformatics capability accessible to any scientist.

"This is a major advance because cancer sequencing experiments often yield
hundreds of variants, among which only a small fraction are true cancer driver
mutations," said Dan Rhodes, head of Medical Science Informatics for Life
Technologies. "Previously researchers were faced with cumbersome literature
searches or complex bioinformatics approaches to discern drivers from
passenger mutations. The thousands of patient tumor samples driving the
Oncomine Analysis provide both context and confidence for the Gain of Function
or Loss of Function classification. This allows any cancer researcher to
immediately identify likely driver mutations in their sample."

Ion Reporter™ Software is a suite of bioinformatics tools that enables users
to quickly identify and report on biologically relevant mutations.Ion
Reporter^TM Software streamlines data analysis by providing simple tools for
mapping, calling and annotating variants. The Oncomine^® platform is a product
of Compendia Bioscience^®, a preeminent cancer bioinformatics company, which
was purchased by Life Technologies in October 2012.

"Next-generation sequencing of cancer samples identifies many potentially
important variants, particularly if matched germline DNA is not sequenced in
parallel," said Scott Tomlins, M.D., Ph.D., assistant professor, Department of
Pathology, University of Michigan. "Theaddition ofOncomine^® annotations to
Ion Reporter™Software provides the best way to prioritize those mutations
that are likely cancer drivers, based on well-curated supporting evidence
across cancer types."

Life Technologies acquired Compendia Bioscience^® in October 2012. Data
compiled by Compendia comprises one of the world's largest and most
comprehensive sets of mutation profiles, gene expression data and cellular
biomarkers that have been gathered from more than 71,000 cancer patients.
Oncomine^®, a web-based analytics tool, integrates high-throughput cancer
profiling data across a large volume of cancer types that provides researchers
with valuable insights into biology, regulation, pathways, drug response, and
patient populations.

Life Technologies Welcome Reception at AACR 2013 - Applications in Cancer
Research Using Life Technologies Solutions

Life Technologies will host a pre-show reception on Saturday, April 6, 2013,
6:30 to 9:30 p.m. Speakers will include Gabrielle Zoppoli, MD, PhD., professor
at the University of Genova and IRCCS AOU San Martino IST, Genova, IT. Dr.
Zoppoli is the first recipient of Life Technologies Digital PCR Applications
Grant Program and will present results measuring the Her-2 gene in
borderline-amplified breast cancer research samples using the QuantStudio™ 3D
Digital PCR System.

For a complete description of speakers and topics, please click here.

Products referenced above are For Research Use only, not for use in diagnostic
procedures.

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact:

Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com

Wes Conard
650-243-6019
wes.conard@lifetech.com

SOURCE Life Technologies Corporation
 
Press spacebar to pause and continue. Press esc to stop.